New PALAMIX® vacuum mixing system for bone cement optimises organisation of orthopaedic surgery

Wehrheim, Germany -- April 24, 2017

The innovative design of PALAMIX® allows a high degree of safety and convenience for both personnel and patients.

More efficient organisation of hip and knee joint surgery for the medical staff and patients – these are just a few of the advantages of the new PALAMIX® vacuum mixing system from Heraeus Medical. The new generation makes mixing and application of bone cement even easier and more convenient for permanent anchorage of hip and knee joint prostheses.

Mixing and collecting under vacuum
Both mixing of the cement components, as well as collecting the cement, take place under vacuum. After mixing, the cement is automatically driven to the tip of the cartridge and compacted. This simplifies and accelerates the application process. The result is a homogeneously mixed bone cement without trapped air and thus free of micropores – an essential success factor in modern cementing techniques for longer survival rates for prostheses.

Safety and convenience for personnel and patients
The innovative design of PALAMIX® allows a high degree of safety and convenience for both personnel and patients: PALAMIX® has a filling funnel with two separate sections for powder and liquid. A particle filter in the liquid chamber offers protection against glass particles in the bone cement. This avoids injuries and impairment of the cement's mechanical quality. PALAMIX® is easy to operate and its handling is quick and easy to learn.

One size for different procedures
The new PALAMIX® vacuum mixing system is offered in one size: up to 80g cement in PALAMIX® uno (one cartridge) or up to 160g cement in PALAMIX® duo (2 cartridges). So one vacuum mixing system meets the needs of different procedures. This means: more efficient organisation of surgery, improved storage planning and lower storage costs.

More information: www.herae.us/PALAMIX_EN

###

Heraeus Medical is a leader in the area of bone cements and biomaterials for surgical orthopaedics and trauma surgery. This enables the company to make an important contribution to supporting surgeons and the surgical team and to improve surgery outcomes. In the area of biomaterials, Heraeus Medical focuses on products for use in bone and joint surgery. The core product PALACOS® is considered the gold standard among bone cements and has repeatedly proven itself over five decades of clinical use. PALACOS® R+G - the first bone cement with antibiotics for infection prophylaxis in endoprosthetics - was developed over 45 years ago.

Heraeus, the technology group headquartered in Hanau, Germany, is a leading international family-owned company formed in 1851. With expertise, a focus on innovations, operational excellence and an entrepreneurial leadership, we strive to continuously improve the businesses of our customers around the world.
We create high-quality solutions for our customers and strengthen their long-term competitiveness by combining material expertise with technological know-how. Our ideas are focused on important issues such as the environment, energy, health, mobility and industrial applications. Our portfolio ranges from components to coordinated material systems which are used in a wide variety of industries, including the steel, electronics, chemical, automotive and telecommunications industries.In the 2015 financial year, Heraeus generated revenues without precious metals of €1.9 bn and a total revenue of €12.9 bn. With approximately 12,500 employees worldwide in more than 100 subsidiaries in 38 countries, Heraeus holds a leading position in its global markets. In 2016, the Foundation for Family Businesses named Heraeus as one of the “Top 10 Family Businesses” in Germany.

Contact:
Heraeus Medical GmbH
Lilian Winkler
Manager Communication
Philipp-Reis-Str. 8–13
61273 Wehrheim, Germany
Tel.: +49 6181 352995
E-Mail: Lilian.Winkler(at)heraeus.com

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

This release was published on openPR.